Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer

Lung Cancer

Volumn 45, Issue 1, 2004, Pages 85-91

  Nogami, Naoyuki ^a   Harita, Shingo ^b   Ueoka, Hiroshi ^a   Yonei, Toshiro ^c   Kiura, Katsuyuki ^a   Kamei, Haruhito ^d   Tabata, Masahiro ^a   Segawa, Yoshihiko ^e   Gemba, Kenichi ^f   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b CHUGOKU CENTRAL HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^d Sumitomobesshi Hospital   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f Okayama Rousai Hospital   (Japan)

Author keywords

Docetaxel; Irinotecan; Non platinum regimen; Non small cell lung cancer

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DOCETAXEL; IRINOTECAN; LOPERAMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FLUID RETENTION; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LIVER INJURY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; TAXOIDS;

EID: 2942610606     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.12.008     Document Type: Article

References (24)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
2. Bunn P.A., Kelly K., et al. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 5:1998;1087-1100
3. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
4. Roszkowski K., Pluzanska A., Krzakowski M., et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 27:2000;145-157
5. Ranson M., Davidson N., Nicolson M., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 92:2000;1074-1080
6. Le Chevalier T., Brisgand D., Douillard J.Y., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. 12:1994;360-367
7. Bonomi P., Kim K., Fairclough D., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 18:2000;623-631
8. Kubota K., Watanabe K., Kunitoh H., et al. Final results of a randomized phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small cell lung cancer (NSCLC). Proc. ASCO. 21:2002;296a
9. Yana T., Takada M., Origasa H., et al. New chemotherapy agent plus platinum for advanced non-small cell lung cancer: a meta-analysis. Proc. ASCO. 21:2002;328a
10. Lavelle F., Bissery M.C., Combeau C., et al. Preclinical evaluation of docetaxel (taxotere). Semin. Oncol. 22(Suppl. 4):1995;3-16
11. Fossella F., Pereia J.R., von Pawel J., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: TAX 326 study group. J. Clin. Oncol. 21:2003;3016-3024
12. Hsiang Y.H., Liu L.F., et al. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726
13. Fukuoka M., Niitani H., Suzuki A., et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 10:1992;16-20
14. Ueoka H., Tanimoto M., Kiura K., et al. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group. Br. J. Cancer. 85:2001;9-13
15. Negoro S., Masuda N., Takada Y., et al. CPT-11 Lung Cancer Study Group West: randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer. 88:2003;335-341
16. Matsushita A., Tabata M., Ueoka H., et al. Establishment of a drug sensitivity panel using human lung cancer cell lines. Acta Med. Okayama. 53:1999;67-75
17. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655
18. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 357:2001;1478-1484
19. Kosmidis P., Mylonakis N., Nicolaides C., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J. Clin. Oncol. 20:2002;3578-3585
20. Gridelli C., Gallo C., Shepherd F.A., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trial Group. J. Clin. Oncol. 21:2003;3025-3034
21. Van Meerbeeck J.P., Smit E.F., Lianes P., et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc. ASCO. 20:2001;308a
22. Couteau C., Risse M.-L., Ducreux M., et al. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J. Clin. Oncol. 18:2000;3545-3552
23. Masuda N., Negoro S., Kudoh S., et al. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J. Clin. Oncol. 18:2000;2996-3003
24. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:2000;6921-6926